Therefore, we propose that initial co-treatment of melanoma patients bearing BRAF mutations with an anti-ErbB3 antibody could be a powerful strategy to enhance clinical efficacy of BRAF and MEK inhibitors. This evidence concerns the gene ERBB3 and melanoma.